Asset Details
Do you wish to reserve the book?
Structural basis of μ-opioid receptor targeting by a nanobody antagonist
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Structural basis of μ-opioid receptor targeting by a nanobody antagonist
Do you wish to request the book?
Structural basis of μ-opioid receptor targeting by a nanobody antagonist
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Structural basis of μ-opioid receptor targeting by a nanobody antagonist
2024
Overview
The μ-opioid receptor (μOR), a prototypical G protein-coupled receptor (GPCR), is the target of opioid analgesics such as morphine and fentanyl. Due to the severe side effects of current opioid drugs, there is considerable interest in developing novel modulators of μOR function. Most GPCR ligands today are small molecules, however biologics, including antibodies and nanobodies, represent alternative therapeutics with clear advantages such as affinity and target selectivity. Here, we describe the nanobody NbE, which selectively binds to the μOR and acts as an antagonist. We functionally characterize NbE as an extracellular and genetically encoded μOR ligand and uncover the molecular basis for μOR antagonism by determining the cryo-EM structure of the NbE-μOR complex. NbE displays a unique ligand binding mode and achieves μOR selectivity by interactions with the orthosteric pocket and extracellular receptor loops. Based on a β-hairpin loop formed by NbE that deeply protrudes into the μOR, we design linear and cyclic peptide analogs that recapitulate NbE’s antagonism. The work illustrates the potential of nanobodies to uniquely engage with GPCRs and describes lower molecular weight μOR ligands that can serve as a basis for therapeutic developments.
The µ-opioid receptor is a key clinical target. Here, the authors describe nanobody NbE, a selective and high affinity antagonist, which is downsized to small cyclic peptides. The work enables unique receptor targeting based on nanobody interaction.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 13/106
/ 13/95
/ 14/10
/ 14/28
/ 631/337
/ 82/83
/ Affinity
/ Analgesics, Opioid - chemistry
/ Analgesics, Opioid - metabolism
/ Analgesics, Opioid - pharmacology
/ Animals
/ Fentanyl
/ Humanities and Social Sciences
/ Humans
/ Ligands
/ Morphine
/ Peptides
/ Peptides, Cyclic - chemistry
/ Peptides, Cyclic - metabolism
/ Peptides, Cyclic - pharmacology
/ Receptors, Opioid, mu - antagonists & inhibitors
/ Receptors, Opioid, mu - chemistry
/ Receptors, Opioid, mu - metabolism
/ Science
/ Single-Domain Antibodies - chemistry
